Your browser doesn't support javascript.
loading
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Ljungman, Per; Schmitt, Michael; Marty, Francisco M; Maertens, Johan; Chemaly, Roy F; Kartsonis, Nicholas A; Butterton, Joan R; Wan, Hong; Teal, Valerie L; Sarratt, Kendra; Murata, Yoshihiko; Leavitt, Randi Y; Badshah, Cyrus.
Afiliação
  • Ljungman P; Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
  • Schmitt M; University of Heidelberg, Germany.
  • Marty FM; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Maertens J; Universitaire Ziekenhuizen Leuven, Belgium.
  • Chemaly RF; University of Texas, MD Anderson Cancer Center, Houston.
  • Kartsonis NA; Merck & Co., Inc., Kenilworth, New Jersey.
  • Butterton JR; Merck & Co., Inc., Kenilworth, New Jersey.
  • Wan H; Merck & Co., Inc., Kenilworth, New Jersey.
  • Teal VL; Merck & Co., Inc., Kenilworth, New Jersey.
  • Sarratt K; Merck & Co., Inc., Kenilworth, New Jersey.
  • Murata Y; Merck & Co., Inc., Kenilworth, New Jersey.
  • Leavitt RY; Merck & Co., Inc., Kenilworth, New Jersey.
  • Badshah C; Merck & Co., Inc., Kenilworth, New Jersey.
Clin Infect Dis ; 70(8): 1525-1533, 2020 04 10.
Article em En | MEDLINE | ID: mdl-31179485
BACKGROUND: In a phase 3 trial, letermovir reduced clinically significant cytomegalovirus infections (CS-CMVi) and all-cause mortality at week 24 versus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) recipients. This post hoc analysis of phase 3 data further investigated the effects of letermovir on all-cause mortality. METHODS: Kaplan-Meier survival curves were generated by treatment group for all-cause mortality. Observations were censored at trial discontinuation for reasons other than death or at trial completion. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox modeling, adjusting for risk factors associated with mortality. RESULTS: Of 495 patients with no detectable CMV DNA at randomization, 437 had vital-status data available through week 48 post-HCT at trial completion (101 deaths, 20.4%). Following letermovir prophylaxis, the HR for all-cause mortality was 0.58 (95% CI, 0.35-0.98; P = .04) at week 24 and 0.74 (95% CI, 0.49-1.11; P = .14) at week 48 post-HCT versus placebo. Incidence of all-cause mortality through week 48 post-HCT in the letermovir group was similar in patients with or without CS-CMVi (15.8 vs 19.4%; P = .71). However, in the placebo group, all-cause mortality at week 48 post-HCT was higher in patients with versus those without CS-CMVi (31.0% vs 18.2%; P = .02). The HR for all-cause mortality in patients with CS-CMVi was 0.45 (95% CI, 0.21-1.00; P = .05) at week 48 for letermovir versus placebo. CONCLUSIONS: Letermovir may reduce mortality by preventing or delaying CS-CMVi in HCT recipients. CLINICAL TRIALS REGISTRATION: clinicaltrials.gov, NCT02137772.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Infecções por Citomegalovirus / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Infecções por Citomegalovirus / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article